<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983706</url>
  </required_header>
  <id_info>
    <org_study_id>IUNU-PC-110</org_study_id>
    <nct_id>NCT04983706</nct_id>
  </id_info>
  <brief_title>Optimization of the Core Number and Location for Targeted Prostate Biopsy</brief_title>
  <official_title>An Exploratory Study of Optimizing the Core Number and Location for MRI/Ultrasound Fusion Targeted Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of core number and location optimization for&#xD;
      targeted prostate biopsy on pathological accuracy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center prospective study. The investigators perform MRI/US image fusion&#xD;
      targeted saturation biopsy on prostate lesions with PI-RADS score 4, to investigate the&#xD;
      effect of core number and location optimization for targeted prostate biopsy on pathological&#xD;
      accuracy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The significant prostate cancer detection rate with different combinations of core number and location in the targeted saturated biopsy area</measure>
    <time_frame>When histology results available, at an expected average of 3 days post-biopsy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MRI/Ultrasound Fusion Saturation Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI/Ultrasound Fusion Saturation Biopsy</intervention_name>
    <description>MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.</description>
    <arm_group_label>MRI/Ultrasound Fusion Saturation Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men more than 18 years old with clinical suspicion of prostate cancer;&#xD;
&#xD;
          2. Serum PSA ≤ 20 ng/ml within the previous 3 months;&#xD;
&#xD;
          3. No evidence of PSA increase by noncancerous factors, such as catheterization, bladder&#xD;
             stones, or urinary tract infection including bacterial prostatitis;&#xD;
&#xD;
          4. mpMRI PI-RADS V2.1 score ≥4, diameter of ≤2.5 cm；&#xD;
&#xD;
          5. Able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior prostate biopsy or prostate surgery;&#xD;
&#xD;
          2. Prior treatment for prostate cancer;&#xD;
&#xD;
          3. Contraindication to MRI (e.g. claustrophobia, pacemaker);&#xD;
&#xD;
          4. Contraindication to prostate biopsy;&#xD;
&#xD;
          5. Men in whom artifact would reduce the quality of the MRI.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongqian Guo</last_name>
    <phone>8613605171690</phone>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qun Lu</last_name>
    <phone>8615195856020</phone>
    <email>luqun_1989@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongqian Guo, MD</last_name>
      <phone>8613605171690</phone>
      <email>dr.ghq@nju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qun Lu, MD</last_name>
      <phone>8615195856020</phone>
      <email>luqun_1989@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

